TY  - JOUR 
AU  - Ríos-Luci, Carla
AU  - García Alonso, Sara
AU  - Díaz Rodríguez, María Elena
AU  - Nadal Serrano, Mercedes
AU  - Arribas, Joaquín
AU  - Ocaña, Alberto
AU  - Pandiella Alonso, Atanasio
PY  - 2017
SN  - 0008-5472
UR  - http://hdl.handle.net/10366/170892
AB  - [EN]Trastuzumab-emtansine (T-DM1) is an antibody–drug conjugate (ADC) that was approved recently to treat HER2+ breast cancers. Despite its impressive clinical efficacy in many patients, intrinsic and acquired resistance to T-DM1 has emerged as a...
LA  - eng
PB  - American Association for Cancer Research
KW  - Breast cancer
KW  - HER2
KW  - ADC
KW  - T-DM1
KW  - Resistance to therapy
KW  - Breast Neoplasms
KW  - Xenograft Model Antitumor Assays
KW  - Humans
KW  - Antineoplastic Agents
KW  - Lysosomes
KW  - Maytansine
KW  - Drug Resistance
KW  - Gene Expression Profiling
KW  - Animals
KW  - Antibodies
KW  - Immunoconjugates
KW  - Proteolysis
KW  - Mice
TI  - Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity
DO  - 10.1158/0008-5472.CAN-16-3127
T2  - Cancer Research
VL  - 77
M2  - 4639
ER  -